CNBX Pharmaceuticals
Cnnabinoid-based Cancer Therapies
Company Overview
Snapshot
Founded in January 2004 by Eyal Ballan, Zohar Koren, and Itamar Borochov, CNBX Pharmaceuticals operates with 1–10 employees. The company became public on OTC in September 2017, marking a significant milestone in its development.
Business overview
CNBX Pharmaceuticals is developing a platform that utilizes novel drug-screening tools and artificial intelligence to create cannabinoid-based cancer therapies. These therapies are tailored to each patient's specific profile, with the goal of assessing effectiveness on a personalized basis. The company aims to integrate cannabinoids into future cancer treatments and operates in Israel as G.R.I.N Ultra Ltd, where it is licensed by the Ministry of Health to conduct scientific and clinical research on cannabinoid formulations and cancer. It primarily serves the Health Tech & Life Sciences sector, specifically within Pharma & Medical Biotechnology and Medical Cannabis.
Strategic signal
In October 2022, CNBX Pharmaceuticals' patent application, "Composition and Method for Treating Cancer with Cannabinoids," entered the national phase in the US and Israel. This development signals the company's progress in securing intellectual property for its cannabinoid-based cancer therapies, indicating a move towards potential commercialization and validation of its research efforts in a highly regulated market.
Log in to access full profile ›Company Intelligence Q&A
- What is CNBX Pharmaceuticals' primary focus?
- CNBX Pharmaceuticals focuses on developing cannabinoid-based cancer therapies using a platform that integrates novel drug-screening tools and artificial intelligence to personalize treatments.
- When did CNBX Pharmaceuticals become a public company?
- CNBX Pharmaceuticals became public on OTC in September 2017.
- What was a significant intellectual property development for CNBX Pharmaceuticals?
- In October 2022, CNBX Pharmaceuticals' patent application for "Composition and Method for Treating Cancer with Cannabinoids" entered the national phase in the US and Israel.
- What was the company's name change in March 2022?
- In March 2022, Cannabics Pharmaceuticals changed its name to CNBX Pharmaceuticals.
- What research findings did Cannabics Pharmaceuticals announce in May 2020?
- In May 2020, Cannabics Pharmaceuticals announced that specific cultivars were identified to have positive anti-tumor effects on gastric adenocarcinoma.